Summary & Overview
HCPCS J9340: Injection, Thiotepa, 15 mg
HCPCS Level II code J9340 represents the injection of thiotepa, 15 mg, a cytotoxic antineoplastic agent used in certain chemotherapy regimens. This national-level billing code is important for accurate reporting of drug administration, cost tracking, and reimbursement for oncology services delivered in infusion settings. Proper use of J9340 affects claims processing and payment for hospitals, outpatient infusion centers, and oncology clinics.
Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for thiotepa administration, typical sites of service, and the common billing considerations associated with an injectable chemotherapy agent. The publication covers benchmarks for utilization and reimbursement trends where available, payer policy highlights, and coding relationships relevant to service lines that deliver antineoplastic therapies.
The content is intended for billing managers, oncology clinic administrators, and policy analysts seeking a clear reference for HCPCS Level II code J9340. Data not provided in the input—such as specific modifier usage patterns, associated ICD-10 diagnoses, or payer-specific pricing—is identified as unavailable in the source.
Billing Code Overview
HCPCS Level II code J9340 denotes an injection of thiotepa, 15 mg. This code represents a single-dose parenteral administration of the antineoplastic agent thiotepa, most commonly used in oncologic treatment regimens.
Service Type: Chemotherapy / Antineoplastic Injection
Typical Site of Service: Hospital outpatient infusion center, oncology clinic, or other infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an oncologic diagnosis such as metastatic bladder, ovarian, breast, or other solid tumor being treated with systemic or intravesical chemotherapy that includes thiotepa. The patient presents to an outpatient oncology infusion center or hospital outpatient department for scheduled parenteral administration of J9340 (thiotepa, 15 mg). The clinical workflow includes verification of the chemotherapy order and dose based on body surface area or protocol, review of recent labs (CBC, renal and hepatic function), informed consent, preparation of the drug by pharmacy under sterile conditions, administration via intravenous push, short infusion or intravesical instillation as specified by the regimen, monitoring for acute infusion reactions, documentation of lot numbers and vial charges, and post‑administration observation for adverse effects such as myelosuppression, mucositis, or local bladder irritation when used intravesically. Typical sites of service are an ambulatory infusion center, hospital outpatient department, or inpatient oncology unit depending on patient acuity and regimen. Common modifiers that may accompany the claim reflect physician services, unusual effort, or site/technical distinctions during administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Physician or other qualified health care professional service | When a qualifying service is performed by the reporting practitioner in addition to drug administration (e.g., evaluation and management tied to the infusion). |